
Fred M. Teskin
Examiner (ID: 8137, Phone: (571)272-1116 , Office: P/1762 )
| Most Active Art Unit | 1762 |
| Art Unit(s) | 2899, 1505, 1713, 1796, 1762 |
| Total Applications | 3761 |
| Issued Applications | 3177 |
| Pending Applications | 144 |
| Abandoned Applications | 473 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 11528653
[patent_doc_number] => 20170088631
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-03-30
[patent_title] => 'NOVEL IMMUNOCONJUGATES'
[patent_app_type] => utility
[patent_app_number] => 15/200507
[patent_app_country] => US
[patent_app_date] => 2016-07-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 42
[patent_figures_cnt] => 42
[patent_no_of_words] => 51828
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15200507
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/200507 | Immunoconjugates | Jun 30, 2016 | Issued |
Array
(
[id] => 13117937
[patent_doc_number] => 10077313
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-09-18
[patent_title] => Anti-CD123 antibodies and conjugates and derivatives thereof
[patent_app_type] => utility
[patent_app_number] => 15/195401
[patent_app_country] => US
[patent_app_date] => 2016-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 53
[patent_figures_cnt] => 54
[patent_no_of_words] => 62425
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15195401
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/195401 | Anti-CD123 antibodies and conjugates and derivatives thereof | Jun 27, 2016 | Issued |
Array
(
[id] => 11092354
[patent_doc_number] => 20160289323
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-10-06
[patent_title] => 'ANTIBODY MOLECULES HAVING BINDING SPECIFICITY FOR HUMAN IL-13'
[patent_app_type] => utility
[patent_app_number] => 15/180916
[patent_app_country] => US
[patent_app_date] => 2016-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 20754
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 15
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15180916
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/180916 | Isolated DNA sequences encoding, and methods for making, antibody molecules having binding specificity for human IL-13 | Jun 12, 2016 | Issued |
Array
(
[id] => 11436102
[patent_doc_number] => 20170037123
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-02-09
[patent_title] => 'ANTI-HUMAN IL-21 ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 15/177914
[patent_app_country] => US
[patent_app_date] => 2016-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23820
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15177914
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/177914 | ANTI-HUMAN IL-21 ANTIBODIES | Jun 8, 2016 | Abandoned |
Array
(
[id] => 12790810
[patent_doc_number] => 20180155439
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-07
[patent_title] => Compositions and Conjugates Comprising an Interleukin and Polypeptides That Specifically Bind TGF-beta
[patent_app_type] => utility
[patent_app_number] => 15/735158
[patent_app_country] => US
[patent_app_date] => 2016-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18537
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15735158
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/735158 | Compositions and Conjugates Comprising an Interleukin and Polypeptides That Specifically Bind TGF-beta | Jun 7, 2016 | Pending |
Array
(
[id] => 15571545
[patent_doc_number] => 10576131
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-03-03
[patent_title] => IL-23-p19 vaccines
[patent_app_type] => utility
[patent_app_number] => 15/569303
[patent_app_country] => US
[patent_app_date] => 2016-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 11864
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15569303
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/569303 | IL-23-p19 vaccines | Jun 2, 2016 | Issued |
Array
(
[id] => 12091297
[patent_doc_number] => 20170348389
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-12-07
[patent_title] => 'TREATING LIVER DISEASES WITH INTERLEUKIN 24'
[patent_app_type] => utility
[patent_app_number] => 15/173570
[patent_app_country] => US
[patent_app_date] => 2016-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 17483
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15173570
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/173570 | TREATING LIVER DISEASES WITH INTERLEUKIN 24 | Jun 2, 2016 | Abandoned |
Array
(
[id] => 12448572
[patent_doc_number] => 09982043
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-05-29
[patent_title] => Use of IL-20 antagonists for treating pancreatic cancer
[patent_app_type] => utility
[patent_app_number] => 15/173560
[patent_app_country] => US
[patent_app_date] => 2016-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 15606
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15173560
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/173560 | Use of IL-20 antagonists for treating pancreatic cancer | Jun 2, 2016 | Issued |
Array
(
[id] => 12808771
[patent_doc_number] => 20180161427
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-14
[patent_title] => COMBINATION OF AN ANTI-IL-10 ANTIBODY AND A CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 15/577377
[patent_app_country] => US
[patent_app_date] => 2016-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17890
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15577377
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/577377 | COMBINATION OF AN ANTI-IL-10 ANTIBODY AND A CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER | May 25, 2016 | Abandoned |
Array
(
[id] => 13386471
[patent_doc_number] => 20180244777
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-30
[patent_title] => Novel Treatment Methods Based on Multifunctional Molecules
[patent_app_type] => utility
[patent_app_number] => 15/575049
[patent_app_country] => US
[patent_app_date] => 2016-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23836
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15575049
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/575049 | Novel Treatment Methods Based on Multifunctional Molecules | May 17, 2016 | Abandoned |
Array
(
[id] => 13106851
[patent_doc_number] => 10072058
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-09-11
[patent_title] => Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates
[patent_app_type] => utility
[patent_app_number] => 15/142169
[patent_app_country] => US
[patent_app_date] => 2016-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 14
[patent_no_of_words] => 11503
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15142169
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/142169 | Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates | Apr 28, 2016 | Issued |
Array
(
[id] => 11053379
[patent_doc_number] => 20160250340
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-01
[patent_title] => 'POLYMER CONJUGATES OF INTERFERON BETA-1a AND USES'
[patent_app_type] => utility
[patent_app_number] => 15/131233
[patent_app_country] => US
[patent_app_date] => 2016-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 20224
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15131233
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/131233 | POLYMER CONJUGATES OF INTERFERON BETA-1a AND USES | Apr 17, 2016 | Abandoned |
Array
(
[id] => 11083782
[patent_doc_number] => 20160280747
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-09-29
[patent_title] => 'ANTICALINS'
[patent_app_type] => utility
[patent_app_number] => 15/092566
[patent_app_country] => US
[patent_app_date] => 2016-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 16008
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15092566
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/092566 | ANTICALINS | Apr 5, 2016 | Abandoned |
Array
(
[id] => 12676015
[patent_doc_number] => 20180117171
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-03
[patent_title] => IMMUNOCONJUGATES FOR PROGRAMMING OR REPROGRAMMING OF CELLS
[patent_app_type] => utility
[patent_app_number] => 15/563878
[patent_app_country] => US
[patent_app_date] => 2016-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44533
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15563878
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/563878 | IMMUNOCONJUGATES FOR PROGRAMMING OR REPROGRAMMING OF CELLS | Mar 31, 2016 | Abandoned |
Array
(
[id] => 15975697
[patent_doc_number] => 10668150
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-02
[patent_title] => IL33 form, mutated forms of IL33, antibodies, assays and methods of using the same
[patent_app_type] => utility
[patent_app_number] => 15/562228
[patent_app_country] => US
[patent_app_date] => 2016-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 58
[patent_figures_cnt] => 61
[patent_no_of_words] => 93775
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15562228
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/562228 | IL33 form, mutated forms of IL33, antibodies, assays and methods of using the same | Mar 29, 2016 | Issued |
Array
(
[id] => 15913057
[patent_doc_number] => 10653750
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-05-19
[patent_title] => Use of CCL2 to inhibit abnormal uterine bleeding
[patent_app_type] => utility
[patent_app_number] => 15/561158
[patent_app_country] => US
[patent_app_date] => 2016-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 32
[patent_no_of_words] => 11587
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15561158
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/561158 | Use of CCL2 to inhibit abnormal uterine bleeding | Mar 22, 2016 | Issued |
Array
(
[id] => 10997435
[patent_doc_number] => 20160194381
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-07-07
[patent_title] => 'METHODS AND COMPOSITIONS FOR TREATMENT OF RETINOID-RESPONSIVE CONDITIONS'
[patent_app_type] => utility
[patent_app_number] => 15/077035
[patent_app_country] => US
[patent_app_date] => 2016-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 18045
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15077035
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/077035 | METHODS AND COMPOSITIONS FOR TREATMENT OF RETINOID-RESPONSIVE CONDITIONS | Mar 21, 2016 | Abandoned |
Array
(
[id] => 12904603
[patent_doc_number] => 20180193376
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-12
[patent_title] => INHIBITORS OF PCSK9 FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS
[patent_app_type] => utility
[patent_app_number] => 15/558491
[patent_app_country] => US
[patent_app_date] => 2016-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23410
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15558491
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/558491 | Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders | Mar 17, 2016 | Issued |
Array
(
[id] => 11434831
[patent_doc_number] => 20170035852
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-02-09
[patent_title] => 'METHODS AND USE OF GROWTH HORMONE SUPERGENE FAMILY PROTEIN ANALOGS FOR TREATMENT OF RADIATION EXPOSURE'
[patent_app_type] => utility
[patent_app_number] => 15/073246
[patent_app_country] => US
[patent_app_date] => 2016-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 23914
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15073246
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/073246 | Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure | Mar 16, 2016 | Issued |
Array
(
[id] => 16605960
[patent_doc_number] => 10906952
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-02-02
[patent_title] => Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15Ra and therapeutic uses thereof
[patent_app_type] => utility
[patent_app_number] => 15/556282
[patent_app_country] => US
[patent_app_date] => 2016-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 26
[patent_no_of_words] => 26238
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15556282
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/556282 | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15Ra and therapeutic uses thereof | Mar 6, 2016 | Issued |